Highlights Genmab A/S Nasdaq

Equities

GMAB

US3723032062

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-12 pm EDT			5-day change	1st Jan Change
26.77 ^USD	-2.01%		-6.85%	-15.92%

Jun. 10	Transcript : Genmab A/S Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM
Jun. 04	Truist Securities Raises Price Target on Genmab to $53 From $50, Maintains Buy Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study	Jun. 03	MT
Genmab A/S Announces Data from the Phase 2 Innovatv 207 Trial, Investigating Tisotumab Vedotin	Jun. 03	CI
Genmab A S and BioNTech SE Announces Initial Data from the Ongoing Phase 2 Trial	Jun. 03	CI
Genmab Announces Initial Data from Phase 2 Cancer Treatment Trial	Jun. 03	MT
Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma	Jun. 02	CI
Genmab A/S and Biontech SE Announce Initial Data from the Phase 2 Gct1046-04 Trial (NCT05117242) Evaluating Acasunlimab	Jun. 01	CI
Genmab A/S Reaffirms Financial Guidance for 2024	May. 21	CI
Genmab A/S completed the acquisition of ProfoundBio, Inc.	May. 20	CI
Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation'	May. 15	MT
Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association Congress	May. 14	CI
GENMAB : A good start to 2024; guidance unchanged	May. 03
Genmab Posts Q1 Net Profit Surge; Revenue Jumps	May. 02	MT
Genmab Reports Higher Interim Q1 Results; Maintains 2024 Guidance	May. 02	MT
Tranche Update on Genmab A/S's Equity Buyback Plan announced on March 1, 2021.	May. 02	CI
Tranche Update on Genmab A/S's Equity Buyback Plan announced on March 25, 2024.	May. 02	CI
Genmab A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Pfizer, Genmab Say FDA Approves Tivak to Treat Cervical Cancer	Apr. 30	MT
Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer	Apr. 29	CI
Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug	Apr. 16	MT
Health Care Slips on Risk Bias -- Health Care Roundup	Apr. 11	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GENMAB : A good start to 2024; guidance unchanged

May 03, 2024 at 01:08 pm EDT